Solvonis Announces Result of AGM

AI SummaryClose X

Solvonis Therapeutics plc announced that all resolutions were passed at its Annual General Meeting, with strong shareholder support for receiving the 2025 accounts, approving the remuneration policy and report, re-appointing auditors and directors, and authorizing the directors to allot equity and disapply pre-emption rights. The company, focused on CNS disorders, highlighted progress in its Alcohol Use Disorder programs (SVN-001 and SVN-002) and its discovery programs for PTSD, stimulant use disorder, and depression, aiming to create long-term shareholder value.

Disclaimer*

UK 100

Latest directors dealings